ANACOR TO PRESENT AT J.P. MORGAN HEALTHCARE CONFERENCE

Palo Alto, Calif. - January 11, 2010 - Anacor Pharmaceuticals announced today that David Perry, Chief Executive Officer, will provide a company overview at the J.P. Morgan Healthcare Conference at 1:30p.m. PT on Thursday, January 14, 2010 in San Francisco, CA.

About Anacor Pharmaceuticals
Anacor is a biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform. Anacor focused initially on developing topical applications of its compounds to treat fungal, bacterial and inflammatory diseases. In addition, the Company is developing systemic antibacterial therapeutics under a research and development agreement with GSK. Anacor's most advanced product candidate is AN2690, a novel topical antifungal in development for the treatment of toenail onychomycosis, which is a fungal infection of the nail and nail bed. AN2690 is licensed to Merck & Co., Inc., under a worldwide development and commercialization agreement for all indications including the treatment of onychomycosis. For more information visit www.anacor.com.

Contact:
Anne Bowdidge
Investor Relations
650-543-7575